Volume 11 Supplement 1

7th Congress of International Society of Systemic Auto-Inflammatory Diseases (ISSAID)

Open Access

PW02-020 - Colitis revealing mevalonate kinase deficiency

  • L Michael1,
  • J Camille2 and
  • BM Brigitte3
Pediatric Rheumatology201311(Suppl 1):A160

https://doi.org/10.1186/1546-0096-11-S1-A160

Published: 8 November 2013

Introduction

Hyperimmunoglobulinemia D (HIDS) is the less severe form of mevalonate kinase deficiency (MKD) caused by recessive inherited mutation in the mevalonate kinase gene (MVK). HIDS is characterized by febrile attacks, often associated with transient digestive manifestations, such as abdominal pain, diarrhea and vomiting.

Case report

Here we report for the first time two patients with MKD revealed by a severe neonatal colitis. Both patients had chronic bloody diarrhea and failure to thrive, one patient since the age of one month and the other twelve days. Total parenteral nutrition was required. A marked elevation of acute phase reactants was present, and no evidence of infection was found. In patient 1, ileocolonoscopy revealed an ulcerative colitis at the age of 5 months. Patient 2 suffered from enterocolitis and shock, associated with multiple bowel adhesions at age 5 weeks; the rectosigmoidoscopy showed aphtoid lesions of the sigmoid colon. Pathological findings of colonic biopsies revealed a dense polymorph inflammatory infiltrate associated with deep ulcerations. Febrile attacks occurred 2 months after the onset of digestive symptoms in patient 1, and at onset of disease in patient 2. Genomic sequencing of the MVK gene revealed compound heterozygous mutations in both patients. Anti-interleukin 1 (Anti-IL1) agent (anakinra) produced long-term remission of all digestive features and laboratory parameters.

Discussion

This report emphasizes that MKD may be the cause of severe early-onset inflammatory colitis, and must be considered by physicians, even in the absence of fever, after ruling out infections. Anti-IL1 therapy may result in a dramatic improvement of MKD-related inflammatory bowel disease.

Disclosure of interest

None declared.

Authors’ Affiliations

(1)
Hopital Robert Debré
(2)
CHI Créteil
(3)
Rhumatology, Hôpital Necker Enfants Malades

References

  1. van der Hilst JC, Bodar EJ, Barron KS, Frenkel J, Drenth JP, van der Meer JW: Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine. 2008, 87 (6): 301-310. 10.1097/MD.0b013e318190cfb7.View ArticlePubMedGoogle Scholar
  2. Bader-Meunier B, Florkin B, Sibilia J, Acquaviva C, Hachulla E, Grateau G: Mevalonate kinase deficiency: a survey of 50 patients. Pediatrics. 2011, 128 (1): e152-159. 10.1542/peds.2010-3639.View ArticlePubMedGoogle Scholar
  3. Touitou I, Lesage S, McDermott M, Cuisset L, Hoffman H, Dode C: Infevers: an evolving mutation database for auto-inflammatory syndromes. Human mutation. 2004, 24 (3): 194-198. 10.1002/humu.20080.View ArticlePubMedGoogle Scholar
  4. Cailliez M, Garaix F, Rousset-Rouviere C, Bruno D, Kone-Paut I, Sarles J: Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis. Journal of inherited metabolic disease. 2006, 29 (6): 763-View ArticlePubMedGoogle Scholar
  5. Nimubona L, Laloum D, Rolland MO, Read MH, Guillois B, Duhamel JF: An intestinal obstruction in an eight-month-old child suffering from mevalonic aciduria. Acta paediatrica. 2002, 91 (6): 714-716. 10.1111/j.1651-2227.2002.tb03308.x.View ArticlePubMedGoogle Scholar
  6. Ruemmele FM, El Khoury MG, Talbotec C, Maurage C, Mougenot JF, Schmitz J: Characteristics of inflammatory bowel disease with onset during the first year of life. Journal of pediatric gastroenterology and nutrition. 2006, 43 (5): 603-609. 10.1097/01.mpg.0000237938.12674.e3.View ArticlePubMedGoogle Scholar

Copyright

© Michael et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement